Andrew Chatfield

Andrew Chatfield is the Transformation Office Lead and VP of Global Hospital & Biosimilars at Pfizer, where they oversee operations for sterile injectables and biotech across multiple global sites. With a significant career spanning from 1992 to 2015, Andrew held key roles at organizations such as Aventis, Fresenius Kabi, Mylan, and Hospira, leading critical projects in manufacturing and operations. They earned an MBA from the University of East Anglia and a BEng in Chemical Engineering from Loughborough University. Andrew's extensive experience includes strategic leadership in global supply chains and product launches in leading pharmaceutical markets.